GlassScriptPhysician profile
Katie Johnson
NPI 1679022545
$8,166.13
in general payments reported to CMS, 2019-2025
58 companies · $3,196 in 2025
The $3,196 reported for 2025 was more than what 98% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $426 · 2022: $2,414 · 2023: $1,169 · 2024: $962 · 2025: $3,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,227 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,226.56 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| G1 Therapeutics, INC. | $1,339.91 | 2022-2023 | Cosela |
| Janssen Biotech, INC. | $957.53 | 2022-2025 | Rybrevant, Carvykti, Erleada |
| Abbvie INC. | $549.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $541.61 | 2022-2025 | Lynparza, Tagrisso, Calquence |
| Merck Sharp & Dohme LLC | $364.56 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $335.57 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $280.41 | 2023-2024 | Libtayo |
| United Therapeutics Corporation | $226.63 | 2021-2025 | Tyvaso, Tyvaso |
| Daiichi Sankyo INC. | $214.63 | 2021-2025 | Enhertu |
| Gilead Sciences, INC. | $201.14 | 2021-2024 | Trodelvy |
| Pfizer INC. | $196.70 | 2024-2025 | |
| Glaxosmithkline, LLC. | $180.34 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Bayer Healthcare Pharmaceuticals INC. | $157.00 | 2022-2025 | |
| Eisai INC. | $127.76 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $117.63 | 2024-2025 | Onivyde |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $117.53 | 2022-2025 | Zoladex, Xermelo |
| Global Blood Therapeutics, INC. | $116.79 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $115.35 | 2021-2025 | Opdivo, Opdualag |
| Insmed, INC. | $108.13 | 2021-2022 | |
| Taiho Oncology, INC. | $107.87 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $104.85 | 2022-2025 | |
| Celgene Corporation | $104.03 | 2022-2025 | Reblozyl |
| Takeda Pharmaceuticals U.S.A., INC. | $98.73 | 2023-2025 | Iclusig, Ninlaro, Fruzaqla |
| Exelixis INC. | $93.96 | 2023-2025 | Cabometyx |
| Aveo Pharmaceuticals, INC. | $81.31 | 2025 | |
| Genentech USA, INC. | $81.27 | 2022-2025 | Tecentriq, Lunsumio, Polivy |
| Genmab U.S., INC. | $76.42 | 2024-2025 | Epkinly |
| Beigene USA, INC. | $74.18 | 2023 | Brukinsa |
| Genzyme Corporation | $70.99 | 2022-2025 | |
| Pharmaessentia USA Corporation | $70.04 | 2023-2025 | Besremi |
| Lilly USA, LLC | $62.60 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Deciphera Pharmaceuticals INC. | $60.58 | 2025 | Qinlock, Romvimza |
| Pharmacyclics LLC, An Abbvie Company | $55.62 | 2022-2023 | Imbruvica, Epkinly |
| Adc Therapeutics America, INC. | $51.09 | 2025 | |
| Sobi, INC | $46.74 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $46.54 | 2022-2024 | Tavalisse, Rezlidhia |
| Karyopharm Therapeutics INC. | $46.13 | 2025 | Xpovio |
| Hologic Sales and Service, LLC | $43.29 | 2024-2025 | Aptima |
| Stemline Therapeutics INC. | $41.59 | 2023-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $40.23 | 2025 | Orgovyx |
| Emd Serono, INC. | $38.10 | 2025 | |
| Beone Medicines USA, INC. | $37.29 | 2025 | Tevimbra |
| Electromed, INC. | $36.68 | 2025 | Smartvest |
| Almatica Pharma LLC | $33.38 | 2021 | |
| Mirati Therapeutics, INC. | $33.25 | 2023 | Krazati |
| Sun Pharmaceutical Industries INC. | $28.70 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.66 | 2025 | |
| Seagen INC. | $26.89 | 2021-2023 | Tukysa |
| Novo Nordisk INC | $24.84 | 2021 | |
| Geron Corporation | $22.48 | 2025 | Rytelo |
| Boston Scientific Corporation | $21.99 | 2023 | Wavewriter Alpha Prime 16 |
| Alexion Pharmaceuticals, INC. | $20.94 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $20.06 | 2024 | Givlaari |
| Puma Biotechnology, INC. | $19.19 | 2025 | |
| Fennec Pharmaceuticals, INC. | $18.81 | 2025 | Fyarro |
| Cycle Pharmaceuticals INC | $18.63 | 2025 | Phyrago |
| Servier Pharmaceuticals LLC | $17.80 | 2024 | |
| Amgen INC. | $12.82 | 2023 | Kyprolis, Blincyto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katie Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.